Several studies have demonstrated that the EMT-promoting function of vimentin is associated with poor clinical outcomes in various cancers, including leukemia [6], lung [7], neuroendocrine [8], gastric [9], colorectal [10, 11], cervical [12], and breast [13] cancer. Here, VIM is linked to cancer.